All relevant data are within the manuscript and its Supporting Information files. The sequencing data associated with this study are available in GSE134423.

Introduction {#sec001}
============

The emergence of genome wide high-throughput sequencing technology revealed the intriguing complexity of the human transcriptome and the existence of thousands of long non-coding RNAs (lncRNAs), which are processed similarly to mRNAs but appear not to give rise to functional proteins \[[@ppat.1008390.ref001]\]. Although an increasing number of lncRNAs are implicated in a variety of cellular functions, they do not form a well-defined class of transcripts that act through a common pathway. Thus, most lncRNAs remain poorly characterized mechanistically. The few well-studied examples include lncRNAs that act in the nucleus and regulate gene expression in *cis* or in *trans* through recruitment of proteins or molecular complexes to specific loci \[[@ppat.1008390.ref001],[@ppat.1008390.ref002]\]. LncRNAs can also act as scaffolds that bring together different proteins or bridge protein complexes and specific chromatin regions \[[@ppat.1008390.ref003]\]. In addition, there is a growing list of assigned functions for mature cytoplasmic lncRNAs, such as regulation of translation by hybridization to target mRNAs, functional modulation of cytosolic proteins, and acting as decoys for short RNAs or RNA-binding proteins \[[@ppat.1008390.ref004],[@ppat.1008390.ref005]\].

Members of the family *Herpesviridae* are large DNA viruses that infect a wide range of vertebrates, including humans. They typically cause acute disease associated with lytic infection, followed by benign, life-long persistence involving latent infection with occasional reactivation \[[@ppat.1008390.ref006]\]. Although viruses are known for their compact genomes in which regions not encoding proteins are rare, a number of highly expressed lncRNAs have been identified in herpesviruses and shown to have critical roles. These roles include: regulation of chromatin structure \[[@ppat.1008390.ref007]\], latency establishment, maintenance and reactivation \[[@ppat.1008390.ref008]--[@ppat.1008390.ref010]\], recruitment of cellular transcription factors to viral DNA \[[@ppat.1008390.ref011]\], inhibition of virus-induced apoptosis \[[@ppat.1008390.ref012],[@ppat.1008390.ref013]\], and quenching of cellular miRNAs \[[@ppat.1008390.ref014],[@ppat.1008390.ref015]\]. Human cytomegalovirus (HCMV) is a ubiquitous member of the subfamily *Betaherpesvirinae*, infecting the majority of human population worldwide and leading to severe diseases in newborns and immunocompromised adults. The viral genome is 236 kbp in size and has been estimated to contain at least 170 open reading frames encoding functional proteins \[[@ppat.1008390.ref016],[@ppat.1008390.ref017]\]. Recent studies revealed a more complex expression pattern, characterized by many previously undetected transcribed and translated sequences during lytic and latent infection \[[@ppat.1008390.ref018]--[@ppat.1008390.ref022]\]. In particular, RNA sequencing (RNA-seq) experiments have shown that the majority of polyadenylated viral RNA transcription is committed to the production of four lncRNAs (RNA2.7, RNA1.2, RNA4.9, and RNA5.0; the numbers represent transcript lengths in kb) \[[@ppat.1008390.ref019]\]. These lncRNAs are expressed by low- and high-passage HCMV isolates during lytic and latent infection \[[@ppat.1008390.ref020],[@ppat.1008390.ref021],[@ppat.1008390.ref023]\]. Although their high expression levels and widespread occurrence suggests an important function in viral propagation, the functions of these viral lncRNAs remain largely unknown.

Here, we have analyzed the expression and localization of the four major HCMV lncRNAs. Whereas RNA1.2, RNA2.7 and RNA5.0 are distributed in the cytoplasm, RNA4.9 is localized to the nuclear viral replication compartment. We found that ablating RNA4.9 expression inhibited viral DNA synthesis and consequently reduced viral titers. We further demonstrate that RNA4.9 forms an R-loop involving the unusually G+C-rich region at its 5' end and that it regulates viral DNA replication and also effects the levels of the HCMV single-stranded DNA-binding protein (ssDBP; encoded by gene UL57). Moreover, we discovered that murine cytomegalovirus (MCMV) encodes a lncRNA with a similar genomic localization and G+C-composition to those of HCMV RNA4.9. These results suggest a novel mechanism, conserved among betaherpesviruses, by which a viral lncRNA, embedded in the origin of viral DNA replication (*oriLyt*), regulates viral DNA replication and may play a role in coupling *oriLyt* activity with the level of ssDBP.

Results {#sec002}
=======

RNA4.9 is concentrated in the viral replication compartment {#sec003}
-----------------------------------------------------------

Our measurements of viral RNA levels during HCMV infection \[[@ppat.1008390.ref024]\] revealed that the levels of HCMV lncRNAs are very high throughout lytic infection of fibroblasts. At 72 hours post infection (hpi), their expression is higher than most viral genes and they greatly outnumber (up to 190- and 95-fold for RNA2.7 and RNA1.2, respectively) the levels of the abundant cellular transcript *actinB* ([Fig 1A](#ppat.1008390.g001){ref-type="fig"}). Since cellular lncRNAs have diverse molecular functions in various cellular compartments, we first investigated the subcellular localization of the HCMV lncRNAs. Using fluorescence *in situ* hybridization (FISH) in HCMV-infected fibroblasts, we found that RNA1.2, RNA2.7 and RNA5.0 localize almost exclusively to the cytoplasm. In contrast, RNA4.9 concentrates in discrete sub-nuclear sites reminiscent of viral DNA replication compartments ([Fig 1B](#ppat.1008390.g001){ref-type="fig"}). The detected signal was confirmed as viral and RNA-specific, since it was detected only in infected cells ([S1A Fig](#ppat.1008390.s001){ref-type="supplementary-material"}) and it was eliminated by pre-treatment of cells with RNase A and not DNase I ([S1B Fig](#ppat.1008390.s001){ref-type="supplementary-material"}). Combining FISH for RNA4.9 with immunofluorescence (IF) staining of the viral DNA polymerase processivity subunit (encoded by gene UL44), we confirmed that RNA4.9 resides within viral DNA replication compartments ([Fig 1C](#ppat.1008390.g001){ref-type="fig"}). In addition, metabolic labeling of nascent viral DNA labeled with ethynyl-2′-deoxyuridine (EdU) and visualized using "Click" chemistry \[[@ppat.1008390.ref025]\] further illustrates that RNA4.9 localizes in the replication compartment ([Fig 1D](#ppat.1008390.g001){ref-type="fig"}). To establish further the nuclear localization of RNA4.9, we performed subcellular fractionation and analyzed RNA 4.9 expression in the nuclear and cytoplasmic fractions. In agreement with FISH staining, RNA4.9 was enriched in the nuclear fraction, whereas RNA2.7 was mostly cytosolic ([S1C Fig](#ppat.1008390.s001){ref-type="supplementary-material"}).

![Expression kinetics and subcellular localization of HCMV lncRNAs.\
**a)** Expression levels of HCMV encoded lncRNAs (RNA2.7, RNA1.2, RNA4.9 and exonic RNA5.0) together with the median expression of viral genes and one host transcript (ACTB) as measured by RNA-seq during HCMV infection in fibroblasts (MOI = 5) \[[@ppat.1008390.ref024]\]. **b)** HCMV lncRNAs were detected by RNA-FISH using fluorescent probes (white) in HCMV Merlin strain-infected fibroblasts at 48 hpi (MOI = 1). **c)** RNA4.9 and the UL44 protein were detected in HCMV Merlin strain-infected fibroblasts at 48 hpi (MOI = 5) using RNA-FISH and IF, respectively. Differential interference contrast (DIC) of the stained cell shows viral DNA replication compartments, indicated by black arrows. **d)** RNA4.9 and nascent DNA were detected in HCMV Merlin strain-infected fibroblasts at 48 hpi (MOI = 3) using RNA-FISH and EdU incorporation followed by labelling with a 6-FAM fluorescent azide using the "Click" chemistry. **b-d)** Nuclei were counterstained with Hoechst (blue, in merge).](ppat.1008390.g001){#ppat.1008390.g001}

Interference with RNA4.9 expression inhibits viral DNA replication and viral titers {#sec004}
-----------------------------------------------------------------------------------

The localization of RNA4.9 to the viral replication compartment hinted to a possible role in DNA replication and motivated us to assess its role during infection. Analysis of RNA4.9 expression kinetics showed that, in agreement with our RNA-seq measurements, RNA4.9 was expressed already at 5 hpi and continually raised as infection progressed ([Fig 2A](#ppat.1008390.g002){ref-type="fig"}). Inhibition of viral DNA replication using viral DNA polymerase inhibitor phosphonoformic acid (PFA) reduced RNA4.9 expression, most likely due to the decrease in available viral genomic template, but did not abolish it ([Fig 2A](#ppat.1008390.g002){ref-type="fig"}). We next asked if the sub-nuclear localization of RNA4.9 is dependent on viral DNA synthesis by blocking viral DNA synthesis and analyzing RNA4.9 and UL44 expression at 48 hpi using FISH and IF, respectively. RNA4.9 levels were reduced by inhibition of viral DNA replication but concentration of RNA4.9 in sub-nuclear sites was not affected by PFA treatment ([Fig 2B](#ppat.1008390.g002){ref-type="fig"}). However, in agreement with previous observations \[[@ppat.1008390.ref026]\], inhibition of viral DNA replication resulted in dispersion of UL44 in the nucleus ([Fig 2B](#ppat.1008390.g002){ref-type="fig"}). Taken together, these results indicate that the initial expression and localization of RNA4.9 occurs independent of viral DNA synthesis.

![RNA4.9 shows immediate early kinetics and its KD inhibits HCMV DNA replication and growth.\
**a)** HCMV Merlin strain-infected fibroblasts (MOI = 1) were harvested at indicated time points. Infected cells were treated with the viral DNA replication inhibitor phosphonoformic acid (PFA) as indicated. Relative levels of RNA4.9 were quantified using RT-qPCR and normalized to the cellular transcript ANXA5. **b)** RNA4.9 and the UL44 protein (white) were detected in HCMV Merlin strain-infected fibroblasts at 48 hpi (MOI = 5) using RNA-FISH and IF, respectively. Infected cells were treated with PFA as indicated. Nuclei were counterstained with Hoechst (blue). **c-f)** Fibroblasts expressing CAS9 and either a control sgRNA or one of two different sgRNAs targeting the RNA4.9 promoter (sgRNA3 and sgRNA5) were infected with HCMV Merlin strain (MOI = 0.1). **c)** Relative levels of RNA4.9 were quantified using RT-qPCR at 48 hpi and normalized to the cellular transcript ANXA5. **d)** Relative viral DNA levels were quantified using qPCR at 48 hpi using UL44 primers, and normalized to the cellular gene B2M. **e)** Viral titers were measured 5 days post infection (dpi) by TCID50. **f)** Relative levels of HCMV immediate early gene UL123 (encoding IE1) and early gene UL44 were quantified by RT-qPCR at 24 and 48 hpi, and late gene UL99 was quantified at 48 hpi. RNA levels were normalized to the cellular ANXA5 transcript. **c-f)** Values and error bars represent the mean and SD of triplicates. A representative analysis of two independent experiments is shown. Two-sided *t*-test was applied (\*\*\*p-value\<0.001, \*\*p-value\<0.01, \*p-value\<0.05, NS, not significant).](ppat.1008390.g002){#ppat.1008390.g002}

Complete deletion of the RNA4.9 gene leads to a non-infectious virus, since it overlaps essential regions of *oriLyt* \[[@ppat.1008390.ref027],[@ppat.1008390.ref028]\]. Therefore, to assess RNA4.9 function, we attempted to knock down (KD) RNA4.9 expression using siRNAs. We transfected fibroblasts with siRNAs targeting RNA4.9 or RNA1.2 (as a control) and infected them with virus for 48 hours. RNA1.2 expression was significantly reduced, but there was no significant reduction in RNA4.9 expression ([S2A Fig](#ppat.1008390.s002){ref-type="supplementary-material"}), probably because the RNAi machinery is located mainly in the cytoplasm and access to nuclear-retained lncRNAs is limited \[[@ppat.1008390.ref029]\]. We further attempted to use chemically modified chimeric DNA antisense oligonucleotides (ASO), which have been used to deplete nuclear RNAs, but, in accordance with reports that ASOs are often inefficient \[[@ppat.1008390.ref030]\], we were not able to ablate RNA4.9 expression ([S2B Fig](#ppat.1008390.s002){ref-type="supplementary-material"}).

We then applied two different approaches aimed at inhibiting RNA4.9 expression while minimally interfering with the integrity of *oriLyt*. The first used the CRISPR--Cas9 system to create deletion mutations around the RNA4.9 promoter. The second used CRISPR interference (CRISPRi), in which a nuclease-inactive derivative of Cas9 is fused to the KRAB repressor domain (dCas9), to bind near the RNA4.9 promoter and block RNA4.9 transcription without introducing mutations \[[@ppat.1008390.ref031]\]. In each approach, two sgRNAs mapping close to the RNA4.9 transcriptional start site (TSS) were selected, and their use resulted in significant RNA4.9 KD ([Fig 2C](#ppat.1008390.g002){ref-type="fig"} and [S2C Fig](#ppat.1008390.s002){ref-type="supplementary-material"}). In both approaches, a control sgRNA was used that did not cause RNA4.9 KD. RNA4.9 KD using both approaches led to reduced viral DNA synthesis ([Fig 2D](#ppat.1008390.g002){ref-type="fig"} and [S2D Fig](#ppat.1008390.s002){ref-type="supplementary-material"}) and viral growth ([Fig 2E](#ppat.1008390.g002){ref-type="fig"} and [S2E Fig](#ppat.1008390.s002){ref-type="supplementary-material"}), but the KD efficiency and the corresponding effects were much greater using CRISPR--Cas9. No effect on expression of immediate early (IE) gene UL123 (encoding IE1) was observed, and a minimal reduction in early gene UL44 expression was detected at 24 hpi, when DNA replication starts. However, expression of early gene UL44 and late gene UL99 was reduced substantially at 48 hpi, when extensive DNA replication takes place ([Fig 2F](#ppat.1008390.g002){ref-type="fig"} and [S2F Fig](#ppat.1008390.s002){ref-type="supplementary-material"}). These results suggest that RNA4.9 expression is important for viral DNA synthesis and growth.

Targeting the RNA4.9 promoter with CRISPR-Cas9 directly inhibits viral DNA replication {#sec005}
--------------------------------------------------------------------------------------

HCMV DNA replication is dependent on early gene expression because it relies on early gene products. In addition, DNA replication affects the levels of early gene expression, as increased levels of viral DNA give rise to more viral transcripts. Therefore, we investigated whether interference with RNA4.9 expression affects early viral gene expression directly, leading to a secondary reduction in viral DNA replication, or whether it affects DNA replication, leading to a secondary effect on early gene expression. This was done by infecting control cells and cells in which RNA4.9 was targeted by CRISPR (RNA4.9-Cas9 KD), in the presence of PFA, which blocks viral DNA synthesis, thus ensuring that any effect on gene expression was directly due to RNA4.9 depletion. Real-time PCR and RNA-seq analysis demonstrated that RNA4.9-Cas9 KD did not result in any other major changes (greater than 2-fold) in viral gene expression ([Fig 3A](#ppat.1008390.g003){ref-type="fig"}, [S3 Fig](#ppat.1008390.s003){ref-type="supplementary-material"} and [S1 Table](#ppat.1008390.s009){ref-type="supplementary-material"}), when viral DNA replication was inhibited. These results suggest that RNA4.9 is involved in viral DNA replication, and that the effect on viral gene expression is a result of the availability of fewer viral template DNA molecules.

![RNA4.9 forms R-loops and its Cas9 KD does not directly affect viral gene expression.\
**a)** Scatter plot presenting canonical viral gene expression in fibroblasts expressing CAS9 and a control sgRNA or a sgRNA targeting the RNA4.9 promoter (sgRNA3), which were infected with HCMV Merlin strain (MOI = 0.01), as measured by RNA-seq at 24 hpi with PFA treatment. The average and SD of two independent experiments is shown. **b)** Fibroblasts were infected with HCMV Merlin strain (MOI = 3) and cells were harvested at 48 hpi for DNA-RNA hybrid IP (DRIP). Enrichment of viral lncRNAs regions (green; RNA4.9 region was quantified using two sets of primers a and b) and an R-loop-forming cellular gene (APOE, blue; positive control) relative to the immunoprecipitation with an isotype control was quantified by qPCR. Fold-enrichment was calculated relative to a non-R-loop-forming cellular gene (SLC22A1). A relative enrichment of 1 represents no enrichment (dashed grey line). Values and error bars represent the average and SD of triplicates. A representative analysis of two independent experiments is shown. One-sided *t*-test was applied and compared to the non-R-loop-forming cellular gene (SLC22A1), (\*\*p-value\<0.01, \*p-value\<0.05, NS, not significant).](ppat.1008390.g003){#ppat.1008390.g003}

The G+C-rich region of RNA4.9 forms RNA-DNA hybrids within *oriLyt* {#sec006}
-------------------------------------------------------------------

The first 800 nucleotides of RNA4.9 are highly G+C-rich (\~80%). G+C-rich islands are often found adjacent to origins of DNA replication in nuclear and mitochondrial genomes, as well as in viral DNA \[[@ppat.1008390.ref032]--[@ppat.1008390.ref034]\]. Transcripts originating from these sites are known to form triplex RNA-DNA structures (R-loops) with their DNA template and to be functionally important for the initiation of DNA replication \[[@ppat.1008390.ref035],[@ppat.1008390.ref036]\]. In cells infected by a gammaherpesvirus, Epstein-Barr virus (EBV), viral replication depends on the formation of an RNA-DNA hybrid at *oriLyt* by the viral G+C-rich BHLF1 transcript \[[@ppat.1008390.ref037]\]. Similarly, the G+C-region of an *oriLyt*-associated transcript is essential for DNA replication of another gammaherpesvirus, Kaposi's sarcoma-associated herpesvirus (KSHV) \[[@ppat.1008390.ref038]\]. RNA-DNA hybrids were previously described within HCMV OriLyt \[[@ppat.1008390.ref039]\]. We therefore examined whether RNA4.9 forms an RNA-DNA hybrid through its G+C-rich domain, using DNA-RNA hybrid immunoprecipitation (DRIP). DNA fragments containing the G+C-rich domain of the RNA4.9 gene were enriched in the pulled down fraction similar to the cellular gene APOE, which is known to form R-loops \[[@ppat.1008390.ref040],[@ppat.1008390.ref041]\]. In contrast, DNA fragments encompassing the RNA1.2 and RNA2.7 genes were not enriched in the pulled down fraction similar to nonrelated genomic regions ([Fig 3B](#ppat.1008390.g003){ref-type="fig"}). These results suggest that RNA4.9 forms an RNA-DNA hybrid via its G+C-rich domain.

Interfering with *oriLyt* activity reduces HCMV ssDBP protein levels {#sec007}
--------------------------------------------------------------------

In EBV, formation of an RNA-DNA hybrid at *oriLyt* is required for recruitment of ssDBP to *oriLyt* \[[@ppat.1008390.ref037]\]. This prompted us to test whether RNA4.9-Cas9 KD affects the recruitment of HCMV ssDBP, encoded by the UL57 gene, to viral DNA replication sites. At 24 and 48 hpi, immunofluorescence analysis revealed that ssDBP was concentrated at specific foci representing viral DNA replication sites, as reported previously (\[[@ppat.1008390.ref042]\]; [Fig 4A and 4B](#ppat.1008390.g004){ref-type="fig"}). However, RNA4.9 KD resulted in a considerable reduction in the ssDBP signal ([Fig 4A and 4B](#ppat.1008390.g004){ref-type="fig"}). A similar reduction in ssDBP signal was observed when these experiments were conducted in the presence of PFA, thus precluding an indirect effect caused by reduction of viral DNA replication ([Fig 4C](#ppat.1008390.g004){ref-type="fig"}). To test the specificity of these effects, we analyzed the expression and localization of the UL84 protein in these cells, as it has been proposed that this protein binds *oriLyt* via an RNA stem-loop \[[@ppat.1008390.ref043],[@ppat.1008390.ref044]\]. However, RNA4.9-Cas9 KD in the presence of PFA did not lead to major changes in the amount or localization of the UL84 protein ([S4A Fig](#ppat.1008390.s004){ref-type="supplementary-material"}).

![RNA4.9-Cas9 KD substantially reduces ssDBP levels.\
Fibroblasts expressing CAS9 and either a control sgRNA or a sgRNA targeting RNA4.9 promoter (sgRNA3 or sgRNA5, as indicated) were infected with HCMV Merlin strain (MOI = 3). **a)** ssDBP (red) was detected by IF at 24 hpi, **b)** 48 hpi or **c)** 48 hpi in the presence of PFA. Cells were counterstained with Hoechst (blue). **d)** ssDBP, IE1/IE2, UL84 and UL44 proteins were detected by immunoblot analysis at 24 or 48 hpi, with and without PFA treatment. GAPDH was used as a loading control. **e)** Quantification of ssDBP levels from the immunoblot analysis in (d), normalized to the levels of GAPDH. **f)** Schematic representation of HCMV *oriLyt* (NC_006273.2), showing the core region (blue) and flanking auxiliary regions (aux, light blue), and genes RNA4.9 (red) and UL57 (yellow). sgRNA PAM sites are indicated in green (sgRNA3--93412 and sgRNA5--93378). **g)** Relative UL57 levels were quantified using RT-qPCR at 24 and 48 hpi, with and without PFA treatment, and normalized to the cellular ANXA5 transcript. Two-sided *t*-tests were applied (\*\*\*p-value\<0.001, \*\*p-value\<0.01, \*p-value\<0.05).](ppat.1008390.g004){#ppat.1008390.g004}

The specific effect of RNA4.9-Cas9 KD on ssDBP levels was further validated by immunoblotting. At 24 hpi, ssDBP levels were drastically reduced by RNA4.9-Cas9 KD ([Fig 4D and 4E](#ppat.1008390.g004){ref-type="fig"}). This effect was specific to ssDBP, as no significant changes were detected in the levels of the early UL44 and UL84 proteins (Figs [4D](#ppat.1008390.g004){ref-type="fig"} and [S4B](#ppat.1008390.s004){ref-type="supplementary-material"}), which participate in DNA replication. Similar levels of IE1 in RNA4.9-Cas9 KD and control cells confirmed that these cells were equally infected. At 48 hpi, RNA4.9 KD resulted in a strong reduction in the levels of the UL44 and UL84 proteins that was mostly dependent on viral DNA replication, as it did not occur in the presence of PFA (Figs [4D](#ppat.1008390.g004){ref-type="fig"} and [S4B](#ppat.1008390.s004){ref-type="supplementary-material"}). In contrast, the reduction in ssDBP was mostly independent of DNA replication, as it also occurred in the presence of PFA ([Fig 4D and 4E](#ppat.1008390.g004){ref-type="fig"}). This indicates that the effect of RNA4.9-Cas9 KD on ssDBP level is independent of the reduction in template molecules.

Since gene UL57 is located immediately next to oriLyt, on the opposite side from the RNA4.9 gene ([Fig 4F](#ppat.1008390.g004){ref-type="fig"}), we assessed whether RNA4.9-Cas9 KD affects the levels of UL57 transcripts. At 24 and 48 hpi, in the presence of PFA, ssDBP levels were reduced greatly by RNA4.9-Cas9 KD (7.8- and 7.7-fold, respectively; [Fig 4E](#ppat.1008390.g004){ref-type="fig"}). In contrast, UL57 transcript levels showed minimal reduction (1.7- and 2-fold, respectively; [Fig 4G](#ppat.1008390.g004){ref-type="fig"}), in accordance with the RNA-seq measurements ([S1 Table](#ppat.1008390.s009){ref-type="supplementary-material"}).

During these experiments, we noticed that our ability to detect ssDBP protein coincided with the onset of DNA replication, as we detected the ssDBP protein only at 24 hpi ([Fig 5A](#ppat.1008390.g005){ref-type="fig"}) and significantly higher levels at 48 hpi, coinciding with the time of substantial viral DNA replication. On the other hand, UL57 transcript levels did not show strong dependency on DNA replication (Figs [5B](#ppat.1008390.g005){ref-type="fig"}, [S5A and S5B](#ppat.1008390.s005){ref-type="supplementary-material"}). In addition, using IF combined with FISH, we detected RNA4.9 in distinct nuclear foci at 12 hpi, whereas we were able to detect the ssDBP only at time points in which viral DNA replication likely initiated and only in proximity to RNA4.9 ([Fig 5C](#ppat.1008390.g005){ref-type="fig"}). Therefore, we tested the possibility that interference with RNA4.9 expression affects ssDBP stability, perhaps as an outcome of faulty unwinding of *oriLyt*. To this end, we ectopically expressed under the same promotor either ssDBP fused to a flag-tag (ssDBP-flag) or mCherry as a control, and measured protein levels during HCMV infection. mCherry expression was detected at 8 hpi, and the level increased moderately at 24hpi ([Fig 5D](#ppat.1008390.g005){ref-type="fig"}). In contrast, ssDBP-flag was detected only at 24 hpi, when viral DNA replication started ([Fig 5E](#ppat.1008390.g005){ref-type="fig"} and [S5B Fig](#ppat.1008390.s005){ref-type="supplementary-material"}), and the level was increased considerably at 48 hpi ([Fig 5E](#ppat.1008390.g005){ref-type="fig"}). Addition of PFA, which inhibits viral DNA synthesis by blocking the viral DNA polymerase, resulted in only a mild reduction of ectopically expressed ssDBP ([Fig 5E](#ppat.1008390.g005){ref-type="fig"}). These results indicate that the initial steps of replication, which precede viral DNA synthesis, such as the *oriLyt* unwinding, are the ones that are likely coupled to ssDBP levels. They also suggest a possible relationship between RNA4.9, *oriLyt* activity and ssDBP expression. However, since these effects were observed by targeting short regions of *oriLyt* using the Cas9 system, it is possible that the physical DNA cleavage rather than RNA4.9 transcription was responsible for inhibition of viral DNA replication and ssDBP expression. Therefore, we examined five different sgRNAs targeting the RNA4.9 TSS region (two of which, sgRNA3 and sgRNA5 were used in all the above experiments) and confirmed that all of them cleave the HCMV genome with similar efficiency ([S6 Fig](#ppat.1008390.s006){ref-type="supplementary-material"}). Despite similar cleavage efficiencies, the three sgRNAs that triggered the most significant reduction in RNA4.9 transcription (sgRNA2, sgRNA3 and sgRNA5 in [Fig 6A](#ppat.1008390.g006){ref-type="fig"}) were most effective in decreasing the levels of ssDBP ([Fig 6B](#ppat.1008390.g006){ref-type="fig"}).

![ssDBP levels are linked to viral DNA replication.\
**a-b)** Fibroblasts were infected with HCMV Merlin strain (MOI = 2) and harvested at indicated time points after infection. **a)** ssDBP was detected by western blot analysis and GAPDH was used as loading control. **b)** In green are ssDBP levels as measured by western blot presented in (a), normalized to GAPDH and in light blue are UL57 transcript levels as quantified by RT-qPCR and normalized to ANXA5. **c)** RNA4.9 (green) and ssDBP (red) were detected in HCMV Merlin strain-infected fibroblasts (MOI = 3) at indicated time points using RNA-FISH and IF, respectively. Nuclei were counterstained with Hoechst (blue). **d-e)** Fibroblasts ectopically expressing either mCherry or ssDBP-flag were infected with HCMV Merlin strain (MOI = 2), harvested at the indicated time points post infection and treated with PFA during infection as indicated. mCherry (d) and ssDBP-flag (e) were detected by immunoblot analysis using anti-mCherry and anti-Flag antibodies, respectively. GAPDH was used as loading control.](ppat.1008390.g005){#ppat.1008390.g005}

![ssDBP levels and viral DNA replication are strongly correlated with RNA4.9 transcription.\
**a-b)** Fibroblasts expressing CAS9 and either a control sgRNA or one of five different sgRNAs targeting RNA4.9, as indicated, were infected with HCMV Merlin strain (MOI = 3), treated with PFA and harvested at 48 hpi. **a)** Relative RNA4.9 levels were quantified using RT-qPCR and normalized to the cellular ANXA5 transcript. **b)** ssDBP was detected by immunoblot analysis and GAPDH was used as a loading control. **c-e)** Fibroblasts infected with the ΔTATA or the parental WT Merlin strain (MOI = 1) were harvested at 48 hpi. **c)** Fibroblasts were treated with PFA during infection. Relative expression levels of indicated viral genes were quantified using RT-qPCR and normalized to the cellular ANXA5 transcript. **d)** Relative viral DNA levels were measured using qPCR using UL44 primers, and normalized to the cellular gene B2M. **e)** ssDBP, IE1/2 and the UL44 protein were detected by immunoblot analysis. Human GAPDH was used as loading control.](ppat.1008390.g006){#ppat.1008390.g006}

The results described above support a direct connection between reduction in RNA4.9 transcription, viral DNA replication and ssDBP expression. To test more directly the effect of RNA4.9 expression on DNA replication, we generated a viral mutant in which the predicted RNA4.9 TATA sequence was deleted (ΔTATA). When comparing this mutant to its parental virus in the presence of PFA, we observed a 2.5-fold reduction in RNA4.9 expression, whereas early and late gene expression did not seem to be affected ([Fig 6C](#ppat.1008390.g006){ref-type="fig"}). The reduction in RNA4.9 transcription coincided with a two-fold reduction in viral DNA replication ([Fig 6D](#ppat.1008390.g006){ref-type="fig"}), further supporting a role for RNA4.9 expression in regulating viral DNA replication. However, no major changes in ssDBP expression were detected ([Fig 6E](#ppat.1008390.g006){ref-type="fig"}), implying that either a more substantial ablation of RNA4.9 is needed to affect ssDBP expression or that there is some effect of the use of CRISPR--Cas9 on expression of ssDBP.

To explore further the complex relationship between RNA4.9, *OriLyt* activity and UL57 expression, we used a previously generated HCMV mutant (OriShift; [Fig 7A](#ppat.1008390.g007){ref-type="fig"}) in which *oriLyt* had been moved \[[@ppat.1008390.ref027]\]. This relocation split the RNA4.9 gene, leaving 3052 bp of the 3' portion at the original site. As expected, the 3' portion of RNA4.9 was not expressed in cells infected with this mutant, whereas expression of the 5' portion relocated with *oriLyt* was partially reduced in the presence of PFA ([Fig 7B](#ppat.1008390.g007){ref-type="fig"}). OriShift did not exhibit a major defect in IE1 expression ([Fig 7C](#ppat.1008390.g007){ref-type="fig"}) in comparison with its parental WT virus, but did show a significant reduction in viral DNA synthesis ([Fig 7D](#ppat.1008390.g007){ref-type="fig"}). Relocation of *oriLyt* and the 5' region of RNA4.9 resulted in a reduction of ssDBP levels in the presence of PFA ([Fig 7C](#ppat.1008390.g007){ref-type="fig"}), but there were no significant changes in UL57 transcript levels ([Fig 7E](#ppat.1008390.g007){ref-type="fig"}). By generating an HCMV mutant in which the 3' portion of RNA4.9 had been deleted (Δ3'), we demonstrated that the reduction in ssDBP levels in OriShift is not due to lack of expression of the 3' portion of RNA4.9 ([S7A and S7B Fig](#ppat.1008390.s007){ref-type="supplementary-material"}). These results show that the interference with *oriLyt* activity caused by its relocation, independent of CRISPR-Cas9 cutting, affects ssDBP expression and that this effect is independent of the 3' region of RNA4.9.

![ssDBP overexpression rescues the defect caused by interference with RNA4.9 expression.\
**a)** Schematic representation of the OriShift mutant \[[@ppat.1008390.ref027]\]. Asterisks mark the genomic location of the shifted *oriLyt* region. **b, c and e)** Fibroblasts were infected with OriShift mutant or the parental AD169 WT virus (MOI = 1), treated with PFA, and harvested at 48 hpi. **b)** Relative RNA4.9 5' and 3' transcript levels were quantified using RT-qPCR and normalized to the cellular ANXA5 transcript. **c)** ssDBP, IE1/2 and the UL44 protein were detected by immunoblot analysis. Human GAPDH was used as loading control. **d)** Fibroblasts were infected with OriShift mutant or the parental AD169 WT virus (MOI = 1) and harvested at 48 hpi, and relative viral DNA levels were quantified by qPCR using UL44 primers and normalized to the cellular gene B2M. **e)** Relative UL57 transcript levels were quantified using RT-qPCR and normalized to the ANXA5 cellular transcript. **f---g)** Fibroblasts overexpressing mCherry as control (yellow) or ssDBP (orange) were either infected with the OriShift mutant or the parental WT virus (MOI = 1) (f) or transduced with CAS9 and either a control sgRNA or a sgRNA targeting RNA4.9 (sgRNA3) and infected with HCMV Merlin strain (MOI = 1) (g). Viral titers were measured at 5 dpi by TCID50. **b, d and e)** Values and error bars represent the average and SD of triplicates. **b-g)** A representative analysis of at least two independent experiments is shown. **b, d and e)** two-sided *t*-test, as well as **f-g)** two-way ANOVA was applied (\*\*\*p-value\<0.001, \*\*p-value\<0.01, \*p-value\<0.05, NS, not significant).](ppat.1008390.g007){#ppat.1008390.g007}

Overexpression of ssDBP rescues the defect caused by interference with *OriLyt* activity {#sec008}
----------------------------------------------------------------------------------------

In light of the drastic reduction observed in ssDBP expression and the essential role of ssDBP in viral DNA replication \[[@ppat.1008390.ref045]\], we investigated whether overexpression of ssDBP could relieve the inhibition of viral DNA replication and growth of the OriShift mutant and in cells in which RNA4.9 promoter was targeted by CRISPR-Cas9. Fibroblasts were transduced with a lentivirus vector encoding ssDBP or mCherry. RNA4.9 KD in these fibroblasts was confirmed ([S7C Fig](#ppat.1008390.s007){ref-type="supplementary-material"}). Significantly, overexpression of ssDBP increased viral DNA replication in cells infected by OriShift or its parental WT virus ([S7D Fig](#ppat.1008390.s007){ref-type="supplementary-material"}), as well as in infected RNA4.9 KD and control cells ([S7E Fig](#ppat.1008390.s007){ref-type="supplementary-material"}), suggesting that the ssDBP may be a limiting factor in viral DNA replication regardless of the interference with *oriLyt*. Overexpression of ssDBP partially rescued the viral growth defect in OriShift ([Fig 7F](#ppat.1008390.g007){ref-type="fig"}) and in RNA4.9-Cas9 KD ([Fig 7G](#ppat.1008390.g007){ref-type="fig"}), but did not increase viral titers in cells infected with WT virus or control KD. Overall, these results indicate that interference with RNA4.9 expression leads to a replication defect that is further enhanced by limiting levels of ssDBP, and that overexpression of ssDBP elevates viral DNA replication, which can compensate for diverse defects in *oriLyt* activity.

MCMV encodes an RNA4.9 counterpart that also plays a role in viral DNA replication {#sec009}
----------------------------------------------------------------------------------

Given that *OriLyt* is located upstream of the gene encoding ssDBP in all betaherpesviruses \[[@ppat.1008390.ref032],[@ppat.1008390.ref046],[@ppat.1008390.ref047]\], and the potential role we discovered for RNA4.9 in regulating viral DNA replication, we investigated whether an RNA4.9 counterpart exists in MCMV. RNA-seq data from MCMV-infected mouse embryonic fibroblasts (MEFs) revealed a corresponding 1.6 kb transcript that is abundant, *oriLyt*-embedded, G+C-rich and lacking ORFs predicted to encode functional proteins, which we named RNA1.6 ([Fig 8A](#ppat.1008390.g008){ref-type="fig"}). In contrast to RNA4.9, which is expressed prior to viral DNA replication, RNA1.6 seemed to be expressed with delayed late kinetics ([S8A Fig](#ppat.1008390.s008){ref-type="supplementary-material"}). The use of sgRNAs targeting RNA1.6 TSS reduced the level of RNA1.6 and inhibited MCMV DNA replication ([Fig 8B and 8C](#ppat.1008390.g008){ref-type="fig"}). Since inhibition of viral DNA replication completely ablated RNA1.6 expression ([S8B Fig](#ppat.1008390.s008){ref-type="supplementary-material"}), it was not possible to test whether RNA1.6 reduction was secondary to inhibition of viral DNA replication. We next tested whether expression of gene M57, encoding MCMV ssDBP, is affected by sgRNAs targeting RNA1.6 TSS sites. To exclude indirect effects due to inhibition of viral DNA replication, we performed the experiments in the presence of PFA. All three sgRNAs tested caused a reduction in ssDBP levels ([Fig 8D](#ppat.1008390.g008){ref-type="fig"}) but no substantial effect on M57 transcript levels ([Fig 8E](#ppat.1008390.g008){ref-type="fig"}). These results suggest that the coupling of ssDBP expression with *oriLyt* activity and a role for *oriLyt*-associated lncRNA in DNA replication may be conserved in MCMV and might represent a conserved feature among betaherpesviruses.

![MCMV RNA1.6 KD is associated with reduced ssDBP levels and inhibition of viral DNA replication.\
**a)** Polyadenylated RNA profile of the MCMV Smith strain (NC_004065.1) genomic locus encompassing M57 (encoding ssDBP, orange), *oriLyt* (black) and RNA1.6 (green) with its G+C-rich region (dashed line), at 72 hpi (MOI = 1). sgRNA PAM sites (shown in red boxes; sgRNA1--93412, sgRNA2--93378, sgRNA3--93495) are displayed. **b-e)** MEFs expressing CAS9 and either a control sgRNA or one of three different sgRNAs targeting the RNA1.6 TSS were infected with MCMV Smith strain (MOI = 1), left untreated (**b,c**) or treated with PFA (**d,e**) and harvested at 20 hpi. **b)** Relative RNA1.6 levels were quantified by RT-qPCR. RNA levels were normalized to mouse GAPDH. **c)** Relative viral DNA levels were quantified by qPCR using primers for gene M54. The murine gene Ino80 was used for normalization. **d)** MCMV ssDBP levels were detected by immunoblot analysis. Mouse GAPDH was used as loading control. **e)** Relative M57 transcript levels were quantified by RT-qPCR. RNA levels were normalized to the mouse transcript GAPDH. **b,c,e)** Values and error bars represent the average and SD of triplicates. A representative analysis of two independent experiments is shown. Two-sided *t*-test was applied (\*\*\*p-value\<0.001, \*\*p-value\<0.01, \*p-value\<0.05, NS, not significant).](ppat.1008390.g008){#ppat.1008390.g008}

Discussion {#sec010}
==========

The functions of HCMV lncRNAs remain largely unknown despite their high abundance during lytic infection. We have shown that, unlike the other three HCMV lncRNAs, RNA4.9 is localized to viral DNA replication sites in the nucleus, and that it is important for efficient viral DNA replication and growth. Furthermore, the use of RNA4.9-Cas9 KD caused a decrease in viral DNA replication and a substantial and specific reduction in ssDBP protein level. Although we were not able to connect unambiguously this reduction in ssDBP levels and the interference with RNA4.9 transcription, our results nonetheless provide strong evidence that ssDBP level is coupled to *oriLyt* activity.

Our findings indicate strongly that RNA4.9 is directly involved in viral DNA replication. First, RNA4.9 is transcribed early in infection and accumulates throughout infection within the viral DNA replication compartment. Second, RNA4.9 is transcribed within *oriLyt* and generates DNA-RNA base pairing, a feature that has been shown to be important for unwinding *oriLyt* in other herpesviruses. Third, RNA4.9-Cas9 KD resulted in substantial and specific reduction of expression of RNA4.9 that coincided with the reduction in viral DNA replication. Fourth, RNA4.9 KD using CRISPRi, in which RNA4.9 transcription is blocked but mutations are not generated, also resulted in a reduction in viral DNA replication. Fifth, a viral mutant lacking the RNA4.9 TATA box and producing reduced levels of RNA4.9 showed a concomitant reduction in viral DNA replication. Together, these findings indicate a direct involvement of RNA4.9 in viral DNA replication. However, it is important to note that, since these experiments involved targeting RNA4.9 transcription, it is not possible to distinguish between the act of transcription and the function of the RNA itself. Indeed, it has been suggested previously that initiation of replication at HCMV *oriLyt* involves transcriptional activation \[[@ppat.1008390.ref048]\], indicating that the act of transcription might be the more important. Finally, in support of the possibility that RNA4.9 transcription *per se* plays a functional role (possibly through the formation of an R-loop), it was recently shown that there is an unusually high level of RNA polymerase II occupancy downstream of the RNA4.9 promoter \[[@ppat.1008390.ref049]\].

HCMV *oriLyt* is a complex locus that has an asymmetric base distribution and contains several inverted and direct repeats \[[@ppat.1008390.ref028]\]. The 5' part (1900 bp) of the RNA4.9 gene includes the G+C-rich region and is embedded in *oriLyt*. This makes it difficult to distinguish between changes in this region that interfere with RNA4.9 transcription and its downstream effects, and changes that interfere directly with *OriLyt* activity. Accordingly, we cannot rule out the possibility that DNA cleavage caused by the Cas9 system affected ssDBP expression and viral DNA replication, but previous work \[[@ppat.1008390.ref050],[@ppat.1008390.ref051]\] and our data show that cleavage of HCMV DNA has only a modest impact on the expression of genes proximal to the cleavage site and minimal impact on HCMV replication. Moreover, the observation that much of the growth defect caused by RNA4.9-Cas9 KD could be rescued by overexpression of ssDBP further indicates that there is no major damage to *OriLyt*.

Our results indicate that ssDBP levels are tightly coupled to *oriLyt* activity; Following either CRISPR--Cas9 targeting or genetic relocation of *oriLyt*, ssDBP levels were substantially reduced. In addition, ssDBP could be detected during infection only when viral DNA replication had initiated and only in proximity to the replication compartment. Furthermore, ectopically expressed ssDBP was detected only at time points at which viral DNA replication had started, despite the transgene being expressed under an exogenous promoter. Although these results show that our ability to detect UL57 expression is coupled to viral DNA replication, treating cells with PFA did not lead to substantial reduction in ectopically expressed ssDBP. Furthermore, PFA treatment led to a reduction in endogenously expressed ssDBP that was comparable to the reduction in other viral early proteins ([Fig 4D](#ppat.1008390.g004){ref-type="fig"}). Since PFA blocks viral DNA replication by inhibiting viral DNA synthesis, these results indicate that the initial steps of replication preceding DNA synthesis, such as *oriLyt* unwinding, are coupled to ssDBP levels rather than viral DNA synthesis itself.

Abundant, G+C-rich, *oriLyt*-embedded transcripts have been shown to be necessary for viral DNA replication in KSHV \[[@ppat.1008390.ref038],[@ppat.1008390.ref052]\] and EBV \[[@ppat.1008390.ref037],[@ppat.1008390.ref053],[@ppat.1008390.ref054]\]. Our results suggest that RNA4.9 forms an RNA-DNA hybrid through its G+C-rich 5' region, which may be important for the unwinding of *oriLyt*. It was indicated previously that two short viral RNAs (estimated by Northern blotting to be 300 and 500 nucleotides long) generate RNA-DNA hybrid regions within *oriLyt* \[[@ppat.1008390.ref039]\]. The sequences encoding these putative RNAs were mapped to the G+C-rich 5' region of RNA4.9 in the opposite orientation relative to RNA4.9. RNA-seq of polyadenylated RNAs did not capture these RNAs \[[@ppat.1008390.ref019],[@ppat.1008390.ref022]\], but small RNA sequencing did detect short RNA fragments that originate from this region \[[@ppat.1008390.ref055]\], indicating that these RNAs, if they are indeed expressed, are not polyadenylated. In light of these data, it remains possible that the transcription pattern around the *oriLyt*, includes additional transcripts, which might be involved in its activity.

Our results support a model in which RNA4.9 transcription enhances the unwinding of *oriLyt* in a process that may involve R-loop formation. ssDBP accumulates concomitantly with *oriLyt* unwinding while perturbation of *oriLy* functions results in reduction in ssDBP expression probably due to its destabilization ([Fig 9](#ppat.1008390.g009){ref-type="fig"}). In herpes simplex virus type 1 (an alphaherpesvirus) ssDBP has been reported to promote the formation of, and bind to, an R-loop *in vitro* \[[@ppat.1008390.ref056]\]. Thus, it is possible that ssDBP is supporting the R-loop formation, resulting in a positive feedback loop that may promote viral DNA replication.

![Proposed model for the regulation of *oriLyt* activity.\
Transcription of RNA4.9 regulates the activity of oriLyt, possibly through R-loop formation at the G+C-rich 5' end of RNA4.9, which may initiate the oriLyt unwinding. The levels of the ssDBP are coupled to the activity of *oriLyt* probably through stabilization of the protein on an unwound origin. Figure was made using BioRender.](ppat.1008390.g009){#ppat.1008390.g009}

Expression of the RNA4.9 counterpart (RNA1.6) in MCMV also appeared to be linked to MCMV DNA replication and ssDBP expression. In addition, our recent transcriptome analysis of HHV6A and HHV6B revealed that these viruses also express lncRNAs that are transcribed from the viral origin of replication in the same orientation as RNA4.9 \[[@ppat.1008390.ref057]\]. These observations indicate that the connection between the ssDBP, the *oriLyt* activity and lncRNA expression might reflect a conserved mechanism that facilitate tight regulation of viral DNA replication in betaherpesviruses.

Expression of ssDBP is essential for HCMV DNA replication \[[@ppat.1008390.ref045]\] and viral growth \[[@ppat.1008390.ref050]\]. Our results show that ssDBP levels are tightly coupled to *oriLyt* activity and that overexpression of ssDBP was capable of partially relieving the viral growth defect caused by RNA4.9-Cas9 KD or by relocation of *oriLyt*. Overexpression of ssDBP also significantly increased the level of viral DNA in WT HCMV-infected cells, suggesting that ssDBP may be a limiting factor in viral DNA replication. Interestingly, ssDBP overexpression did not increase viral titers in WT HCMV-infected cells, implying that the surplus of viral DNA does not translate into virus production. Thus, efficient viral production may require fine-tuning of the levels of ssDBP and genome copies, generating the most effective balance between them and the other resources required.

Our study focused on a particular aspect of RNA4.9 function, and it is likely that this RNA has several roles operating in *cis* and *trans* during infection. For example, it has been suggested that RNA4.9 interacts with the UL84 protein and cellular components of polycomb repression complex 2 (PRC2) to promote transcriptional repression of major immediate-early promoter during HCMV latency \[[@ppat.1008390.ref020]\]. In addition, several lines of evidence indicate additional and possibly independent roles for RNA4.9. First, RNA4.9 molecules accumulate to high levels early during the infectious cycle and appear quickly to outnumber the incoming and replicating genome molecules. Thus, the majority of RNA4.9 molecules are unlikely to be involved directly in R-loop formation. This is further supported by the finding that the majority of RNA4.9 molecules fill the interior of the replication compartment ([Fig 1C](#ppat.1008390.g001){ref-type="fig"}), whereas nascent DNA synthesis occurs at the periphery of these sites ([Fig 1D](#ppat.1008390.g001){ref-type="fig"} and \[[@ppat.1008390.ref026],[@ppat.1008390.ref042]\]). In addition, RNA4.9 molecules were detected in juxtanuclear sites resembling the assembly compartment, whereas RNA1.2, RNA2.7 and RNA5.0 appeared to be excluded ([Fig 1B and 1C](#ppat.1008390.g001){ref-type="fig"}), suggesting that RNA4.9 may also be involved in virion assembly. Finally, the length of RNA4.9 (4.9 kb) and the fact that the region encoding the 3000 bp at the 3' end is located outside essential regions of *oriLyt* point to functions that are independent of RNA4.9 transcription and R-loop formation. Some cellular lncRNAs are known to have structural roles in the nucleus. For example, the *NEAT1* lncRNA has been shown to serve as a platform for recruiting proteins to assemble paraspeckles \[[@ppat.1008390.ref058],[@ppat.1008390.ref059]\]. Also, a nuclear structural role has been suggested recently for two gammaherpesvirus lncRNAs \[[@ppat.1008390.ref060],[@ppat.1008390.ref061]\]. Whether RNA4.9 plays a structural role in the formation of replication compartments is an intriguing possibility that is worthy of further study.

In summary, our study indicates that the level of ssDBP is coupled to *oriLyt* activity during HCMV infection, and supports a role for an abundant viral nuclear lncRNA in the complex regulation of viral DNA replication. The fundamental nature of the mechanisms involved is likely reflected in the existence of counterparts of RNA4.9 in other betaherpesviruses.

Material and methods {#sec011}
====================

Human primary foreskin fibroblast cells and murine embryonic fibroblast (MEF) cells were grown at 37°C in 5% (vol/vol) CO~2~, in Dulbecco's modified Eagle's medium (DMEM, Biological Industries) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (FBS, Life Technologies), 2 mM L-glutamine (Biological Industries), 0.1 mg/mL streptomycin and 100 U/mL penicillin (Biological Industries). The bacterial artificial chromosome (BAC)-derived AD169-GFP (pHG-1) virus and a mutant virus in which *oriLyt* had been moved to a different genomic location (pHG-6, OriShift) were kindly provided by M. Messerle at Hannover Medical School, Germany \[[@ppat.1008390.ref027]\]. The complete genome sequences of these viruses were determined by Illumina sequencing. HCMV strain Merlin was used in all other experiments unless stated otherwise. Multiplicity of infection (MOI; plaque-forming units per cell) values used in HCMV infections are indicated in the Figure legends. MCMV strain Smith-GFP has been described previously \[[@ppat.1008390.ref062]\].

Construction of HCMV RNA4.9 ΔTATA and Δ3'mutants {#sec012}
------------------------------------------------

These mutants were constructed from an HCMV strain Merlin BAC (pAL1111 \[[@ppat.1008390.ref063]\]) by using the recombineering techniques described previously \[[@ppat.1008390.ref063]--[@ppat.1008390.ref066]\]. Briefly, a selectable *KanR*/*RpsL*/*lacZ* cassette flanked by appropriate HCMV sequences was transfected into *Escherichia coli* SW102 cells containing the parental BAC. Clones in which the cassette had recombined homologously into the BAC were selected positively using kanamycin. The inserted cassette was then replaced by the original sequence containing the desired mutation, and clones were selected negatively using streptomycin. BAC DNA was extracted using a Nucleobond BAC 100 kit (Macherey-Nagel) according to the manufacturer's instructions, and virus was reconstituted by transfection into human fibroblast cells using an Amaxa Basic Nucleofector kit for Primary Mammlian Fibroblasts (Lonza). The complete genome sequences of the viruses were determined by Illumina sequencing in order to ensure that the intended mutations were present and no others. Nucleotides 94297--94302 and 96114--99118 were absent from the ΔTATA and the Δ3' mutants, respectively (coordinates from GenBank accession no. AY446894.2).

CRISPR plasmids {#sec013}
---------------

Oligonucleotides specifying 10 single guide RNAs (sgRNAs) mapping within the TATA box region of the HCMV strain Merlin RNA4.9 gene (94,208--94,436, AY446894.2) and three sgRNAs mapping within the TATA box region of the MCMV strain Smith RNA1.6 gene (93328--93554, U68299.1) were designed using benchling (<https://benchling.com/>) and cloned into the lentiviral vector lentiCRISPR v2 (Addgene\#52961) \[[@ppat.1008390.ref067]\]. Using Gibson cloning \[[@ppat.1008390.ref068]\], a derivative of lentiCRISPR v2 was created in which Cas9 was replaced by a nuclease-inactive dCas9 gene fused to the KRAB repressor domain. dCas-KRAB was amplified from pHR-SFFV-KRAB-dCas9-P2A-mCherry \[[@ppat.1008390.ref069]\]. Lentiviral particles were generated by co-transfection of the lentiCRISPR v2 constructs and second-generation packaging plasmids (psPAX2, Addgene\#12260; pMD2.G, Addgene\#12259), using the jetPEI DNA transfection reagent (Polyplus-transfection) with 293T cells according to the manufacturer's instructions. At 48 h post-transfection, supernatants were collected and passed through a 0.45 μm membrane (Millipore).

Cells grown in six-well plates were transduced with lentiviral vector particles in the presence of polybrene (8.33 μg/mL). At 48 h post-transduction, the cells were selected using 1.75 μg/mL puromycin. After 2--3 d of selection, the medium was replaced with fresh DMEM, and the selected cells were infected the next day. RNA4.9 expression was assessed by RT-qPCR. In subsequent experiments, sgRNA3 and sgRNA5 were used with Cas9 to knock down RNA4.9 levels. In the experiments applying dCas9-KRAB, sgRNA3 and sgRNA9 were used. Two different control sgRNAs were employed for HCMV: Control 1 targeting HCMV *oriLyt* without affecting RNA4.9 expression was used in the experiments presented in Figs [2](#ppat.1008390.g002){ref-type="fig"} and [S2](#ppat.1008390.s002){ref-type="supplementary-material"}; Control 2 targeting HCMV gene US2 \[[@ppat.1008390.ref067]\] was used in the remaining experiments. A sgRNA (Control 3) targeting the non-essential MCMV gene m155 was used in the experiments presented in [Fig 8](#ppat.1008390.g008){ref-type="fig"}. Sequences of sgRNAs are listed in [Table 1](#ppat.1008390.t001){ref-type="table"}.

10.1371/journal.ppat.1008390.t001

###### Sequences and genomic locations of the single-guide RNAs used.

![](ppat.1008390.t001){#ppat.1008390.t001g}

  sgRNA       Sequence               Location in HCMV, Merlin
  ----------- ---------------------- --------------------------
  4.9 1       GCGGGCACGCCGGGTTTTAT   94298-94317
  4.9 2       CTCTGAAAACCTATAAAACC   94286-94305
  4.9 3       GGGCTCGCGCTCCCTAGGTG   94208-94227
  4.9 4       AATTACCGCTCCGCCCACCT   94257-94275
  4.9 5       AACCCTGCCGCGGACTGCGC   94327-94346
  4.9 9       GCGGGAGCGGGCGCAGCGTG   94366-94385
  Control 1   CGGGTTTTATAGGTTTTCAG   94288-94307
  Control 2   GTCGGTTCGTCTTCGATCCG   199703-199722
  sgRNA       Sequence               Location in MCMV, Smith
  1.6 1       TATCCGCCACGATGACGCAT   93413-93432
  1.6 2       AAATGGGCGCGGTTTCGCGG   93379-93398
  1.6 3       TCCGAGGCGGCGGTCCGGAG   93496-93515
  Control 3   GACAACGACGATTACTGCGA   215467-215489

TCID~50~ assay {#sec014}
--------------

10^4^ human fibroblasts per well were plated in 96-well plates and infected with 10-fold serial dilutions of media collected from infected cells at 3 and 5 dpi, respectively. After 14 days, the dilutions showing a cytopathic effect were evaluated by light microscopy. TCID50 values per mL were calculated using the Spearman-Kaerber method \[[@ppat.1008390.ref070]\].

Immunofluorescence, EdU staining and FISH {#sec015}
-----------------------------------------

Cells were plated on μ-Slide 8 well chambers (ibidi Gmbh) infected as indicated in the figure legends, washed once with PBS and fixed with 3.7% paraformaldehyde in PBS for 10 min at room temperature (RT). After fixation, the cells were washed twice with PBS and permeabilized with 0.5% (v/v) Triton X-100 in PBS for 20 min.

For metabolic labeling of nascent DNA, EdU (Jena Bioscience GmbH) was added to the culture medium at 10 μM and incubated for 30 min prior to fixation. After fixation and permeablization as described above, the cells were washed twice with PBS and rinsed once with TBS buffer (50 mM Tris-HCl, pH 7.5 and 150 mM NaCl). Azide-substituted 6-FAM fluorophore was conjugated to incorporated EdU using a copper-catalyzed "click" chemistry as described previously \[[@ppat.1008390.ref025]\]. Briefly, cells were incubated for 30 min at RT in conjugation solution (100 mM Tris-HCl pH 8.5, 10 μM fluorescent azide, 1 mM CuSO4 and 100 mM ascorbic acid, the last of which was made freshly and added last) and protected from light. After staining, the cells were washed three times with TBS containing 0.5% (v/v) Triton X-100 and then an additional three times with TBS (without detergent). FISH and IF were performed after EdU staining.

FISH samples were permeabilized with 70% (v/v) ethanol overnight at 4°C. The cells were incubated with FISH wash buffer (10% (v/v) formamide in 2xSSC (0.3 M NaCl, 30 mM sodium citrate, pH 7.0) for 5 min at RT. This was followed by overnight hybridization with FISH hybridization buffer (100 mg/mL dextran sulfate, 10% (v/v) formamide in 2xSSC) containing either 62.5 nM RNA4.9, 62.5 nM RNA2.7, 125 nM RNA1.2 or 125 nM RNA5.0 probes (Stellaris RNA FISH probes, Biosearch Technologies; [S2 Table](#ppat.1008390.s010){ref-type="supplementary-material"}) at 37°C in a humidified incubator and protected from light. The samples were washed twice with warm wash buffer (10% (v/v) formamide in 2xSSC) at 37°C for 30 min followed by a wash with 2xSSC. The nuclei were stained with 1 μg/mL Hoechst in 2xSSC for 5 min at RT, and this was followed by a single wash with 2xSSC. To confirm the specificity of FISH to RNA rather than DNA, fixed and permeabilized cells were incubated prior to FISH with either RNase A (100 μg/mL in 2xSSC) or Turbo DNase I (20 U/mL in DNase reaction buffer, Thermo Fisher Scientific) for 100 min at 37°C and subsequently washed twice with warm (37°C) FISH wash buffer containing 15% (v/v) formamide. FISH probes for RNA5.0 covered the full gene sequence (both exons and the large intron). Detection of the UL44 protein and ssDBP was performed by immunostaining with anti-UL44 antibody (Virusys, CA006, 1:200 in PBS) for 2 h at RT or ssDBP antibody (Virusys, P1209) for 1.5 h at RT. The cells were washed 3 times with PBS and labeled with anti-mouse Alexa 647 conjugated secondary antibody (Jackson ImmunoResearch, 1:200 in PBS) for 1 h at RT. The cells were washed three times with PBS and counterstained with 1 μg/mL Hoechst. Anti-UL44 staining was performed after FISH against RNA4.9, whereas ssDBP detection required staining with primary and secondary antibodies prior to FISH, followed by post-fixation with 2% (w/v) paraformaldehyde in PBS for 10 min at RT. Imaging was performed on a Zeiss Axio Observer Z1 widefield microscope equipped with an X63 oil-immersion objective and an Axiocam 506 mono camera using ZEN imaging software (Zeiss).

Subcellular fractionation {#sec016}
-------------------------

Fractionation of cytosolic and nuclear extracts was performed using the NER-PER Nuclear and Cytoplasmic Extraction Reagents Kit (ThermoFisher) according to the manufacturer's instructions, with the exception that 2 μl SUPERase In (Invitrogen) were added to CER I and 1 μl SUPERase In (Invitrogen) were added to CER II. RNA from these fractions was isolated using Trizol (Sigma-Aldrich) according to the manufacturer's instructions, and was subsequently used for RT-qPCR.

Inhibitors {#sec017}
----------

To inhibit viral DNA synthesis, 400 μg/mL of [sodium phosphonoformate tribasic hexahydrate (PFA, Sigma-Aldrich)](https://www.sigmaaldrich.com/catalog/product/aldrich/p6801?lang=en&region=US) was added to culture medium after the viral inoculum had been removed by washing.

Real-time PCR {#sec018}
-------------

Total cell RNA was extracted and purified using a Quick-RNA MiniPrep kit (Zymo Research), and cDNA was prepared from the RNA using a qScript cDNA synthesis kit (Quantabio) according to the manufacturer's instructions. Total cell DNA was extracted and purified using the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer's instructions. Quantitative PCR was performed using SYBR Green PCR master-mix (ABI) on the StepOnePlus or QuantStudio 6 Flex real-time PCR systems (Life Technologies) with the primers listed below.

The human *ANXA5* and mouse *GAPDH* mRNAs were used to normalize HCMV and MCMV RNA levels, respectively. The human *B2M* and mouse *Ino80* host genes were used to normalize HCMV and MCMV DNA levels, respectively. The relative levels of HCMV and MCMV DNA were estimated by quantification of the HCMV UL44 or UL55 and MCMV M54 genes, respectively. Primer sequences are listed in [Table 2](#ppat.1008390.t002){ref-type="table"}.

10.1371/journal.ppat.1008390.t002

###### Primer sequences used for real-time PCR.

![](ppat.1008390.t002){#ppat.1008390.t002g}

  --------------------------------------------------------------------------
  Gene                Forward primer sequence     Reverse primer sequence
  ------------------- --------------------------- --------------------------
  RNA4.9 a for DRIP   GGGCCTCTGAAAACCTATAAAACCC   ATGGTGCTCCAGGGCGGT

  RNA4.9 5'/\         GGTGACTTTCTCGACGGTTC        ACGCTCCTAGGCTCTCGAC
  RNA4.9 b for DRIP                               

  RNA4.9 3'           GTAAGACGGGCAAATACGGT        AGAGAACGATGGAGGACGAC

  UL55                TGGGCGAGGACAACGAA           TGAGGCTGGGAAGCTGACAT

  UL123               TCCCGCTTATCCTCAGGTACA       TGAGCCTTTCGAGGACATGAA

  UL44                AGCAAGGACCTGACCAAGTT        GCCGAGCTGAACTCCATATT

  UL99                GGGAGGATGACGATAACGAG        TGCCGCTACTACTGTCGTTT

  ANXA5               AGTCTGGTCCTGCTTCACCT        CAAGCCTTTCATAGCCTTCC

  B2M                 TGCTGTCTCCATGTTTGATGTATCT   TCTCTGCTCCCCACCTCTAAGT

  UL57                TGAACGCAGAAACGCAGGAG        GAAATCCGCCTCCACCGTGA

  APOE                CCGGTGAGAAGCGCAGTCGG        CCCAAGCCCGACCCCGAGTA

  SLC22A1             ACTGTCGTGGTGAGTGAGAG        GGAACCTGTCTCTGTCAGCT

  RNA1.2              TGACAACGCCTTGTATAGCC        AGACTGTCGTGGTCGATGAA

  RNA2.7              TCCATGTTTCCATCCTTTCA        AATCAGCGTTGCAGTAGTCG

  GAPDH               TGGTATCGTGGAAGGACTCA        CCAGTAGAGGCAGGGATGAT

  UL32                GGTTTCTGGCTCGTGGATGTCG      CACACAACACCGTCGTCCGATTAC

  M54                 CAGAAAGAGGTCATGACGCG        GAAGGGGAAGTGGAAGACGA

  M57                 ATCTTCAAGGAGCGGATCGT        CTTGTACTGGATCTTGCGCC

  RNA1.6              CTTCCCGGCTACCCTCCT          GAGGAGCCGGACAGGAAC

  Murine GAPDH        TCAAGCTCATTTCCTGGTATGACA    TAGGGCCTCTCTTGCTCAGT

  18S                 CTCAACACGGGAAACCTCAC        CGCTCCACCAACTAAGAACG

  Murine Ino80        GCACTTCCTGGTTTTGCTGT        CACTGACTGGCGTGTTCAGA

  UL57-flag           GGTCTTCTTCTCGGCGAGT         CTTGTCGTCATCGTCTTTGTAGTC

  mCherry             ACCGCCAAGCTGAAGGTGAC        GACCTCAGCGTCGTAGTGGC
  --------------------------------------------------------------------------

siRNA and ASO transfections {#sec019}
---------------------------

Human fibroblasts were refreshed at 4--6 hour prior to transfection with Gibco Opti-MEM I reduced serum medium (ThermoFisher Scientific). siRNAs (20 nM) and ASOs (100 nM), respectively, were transfected into the cells using Lipofectamine RNAiMAX transfection reagent (ThermoFisher Scientific) according to the manufacturer's instructions. On the following day, the cells were washed with complete DMEM and infected with HCMV as described in the figure legends.

siRNA and ASO sequences are listed in [Table 3](#ppat.1008390.t003){ref-type="table"}.

10.1371/journal.ppat.1008390.t003

###### Sequences of siRNAs and ASOs.
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  ----------------- ------------------------------------------------------------------------------------- -----------------------------
  **Name**          **5'- 3' Sequence**                                                                   **3'- 5' Sequence**
  Control siRNA     CGUUAAUCGCGUAUAAUACGCGUAT                                                             AUACGCGUAUUAUACGCGAUUAACGAC
  siRNA RNA1.2      AGAAUCUCAUGAACUAGUCAACCAA                                                             UUGGUUGACUAGUUCAUGAGAUUCUGC
  siRNA RNA4.9 I    UCUGAUUCUCUGAAGAAUCACCGTC                                                             GACGGUGAUUCUUCAGAGAAUCAGAAA
  siRNA RNA4.9 II   AUAUGAUGAACCAAGAAUAAAACTC                                                             GAGUUUUAUUCUUGGUUCAUCAUAUAU
  **Name**          **Sequence**                                                                          
  Control ASO       mG\*mG\*mC\*mG\*mA\*mU\*A\*G\*C\*A\*G\*G\*A\*G\*A\*A\*G\*T\*mC\*mU\*mG\* mA\*mA\*mG   
  ASO RNA4.9 I      mC\*mU\*mA\*mC\*mG\*T\*G\*G\*T\*A\*A\*G\*A\*G\*T\*mC\*mU\*mU\*mG\*mG                  
  ASO RNA4.9 II     mG\*mA\*mC\*mU\*mG\*T\*C\*T\*A\*T\*G\*G\*T\*T\*A\*mU\*mG\*mC\*mA\*mA                  
  ----------------- ------------------------------------------------------------------------------------- -----------------------------

RNA sequencing {#sec020}
--------------

Control cells and cells in which RNA4.9 was targeted by CRISPR were infected for 24h in the presence of PFA, total cell RNA was isolated using Trizol (Sigma-Aldrich) according to the manufacturer's instructions. mRNA was enriched using a Dynabeads mRNA DIRECT purification kit (ThermoFisher Scientific) according to the manufacturer's instructions, and RNA-seq libraries were prepared using a NEBNext Ultra Directional RNA Library Prep kit for Illumina (New England Biolabs) according to the manufacturer's instructions. For RNA-seq of MCMV infected cells, MEFs were harvested 72hpi libraries enriched for the 5' ends of transcripts were prepared as described previously \[[@ppat.1008390.ref071]\].

Illumina sequencing and data analysis {#sec021}
-------------------------------------

Raw sequence reads were generated using a NextSeq500 (Illumina). Prior to alignment, linker and polyA sequences (if present) were removed from the ends of reads. Alignment of the reads to reference sequences was performed using Bowtie (allowing up to two mismatches). Reads aligned to ribosomal RNA were removed, and the remaining reads were aligned to the HCMV strain Merlin or MCMV strain Smith genome sequences (AY446894.2 or U68299.1, respectively). Still-unaligned reads were aligned to 200bp sequences that spanned splice junctions. Reads with unique alignments ([S1 Table](#ppat.1008390.s009){ref-type="supplementary-material"}) were used to compute the total number of reads for each viral gene. Differential expression analysis was done using DESeq2 \[[@ppat.1008390.ref072]\]. For expression levels of the viral lncRNAs, only exonic reads were taken into account.

DNA-RNA immunoprecipitation (DRIP) {#sec022}
----------------------------------

DRIP was performed as described previously \[[@ppat.1008390.ref037]\] with adjustments. Cells were washed three times with PBS, resuspended in lysis buffer (20 mM Tris pH 8, 4 mM EDTA, 20 mM NaCl, 1% (w/v) SDS, supplemented with 0.2 U/mL SUPERase In RNase Inhibitor (AM2694, ThermoFisher Scientific) and 0.7 μg/μL proteinase K; 10^7^ cells/ 500 μL), and incubated at 37°C for 18 h. DNA was extracted using phenol-chloroform and precipitated in 75% (v/v) ethanol, 0.3 M sodium acetate (pH 8) supplemented with 1 μL Glycoblue (ThermoFisher Scientific). DNA was treated with RNaseA (20 ng/μL) in Tris-EDTA buffer and sonicated using a Bioruptor Pico (Diagenode) to generate fragments of 500--800 bp.

8 μg of sonicated DNA was resuspended in immunoprecipitation (IP) buffer (10 mM Sodium phosphate pH 7, 140 mM NaCl and 0.05% (v/v) Triton X-100). Residual sonicated DNA was used as input control for qPCR analysis. Subsequently, either 5 μg of anti-RNA-DNA hybrid antibody (S9.6, MABE1095; MERCK) or the relevant isotype antibody (IgG2s, clone S43.10; Miltenyi Biotec) were added to the DNA and incubated for 18 h at 4°C. 50 μL protein G-Dynabeads (Invitrogen) was added per sample and incubated for 2 h at 4°C. The DNA was eluted by incubating the beads with 250 μL proteinase digestion buffer (50 mM Tris-HCl pH 8, 10 mM EDTA, 0.5% (w/v) SDS and 0.3 μg/μL proteinase K) at 50°C for 3 h while shaking. The DNA was precipitated in 75% (v/v) ethanol and 0.2 M NaCl overnight at -20°C and analyzed by qPCR.

Immunoblot analysis {#sec023}
-------------------

Cells were lysed using ice-cold RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% Na deoxycholate, 50 mM Tris-HCl \[pH 8\] and 0.1% (w/v) SDS) supplemented with a protease inhibitor cocktail (Sigma-Aldrich) for 10 minutes at 4°C. Lysates were cleared by centrifugation at 4°C for 10 minutes at 20800 x g. Proteins were separated on Bolt 4--12% Bis-Tris Plus polyacrylamide gels (ThermoFisher Scientific) and blotted onto nitrocellulose membranes. The membranes were blocked with Odyssey Blocking Buffer (Li-COR) mixed 1:1 with TBST (150mM NaCl, 50 mM Tris-HCl pH7.5 and 0.1% (v/v) Tween), and immunoblotted with primary antibodies (1:1000 in TBST, 5% BSA and 0.05% (w/v) NaN3) for 1 h at RT or overnight at 4°C. This was followed by three washes with TBST. The membranes were probed with secondary antibodies (1:10000 in TBST and 5% (w/v) skimmed milk powder) for 1 h at RT and washed three times with TBST. Fluorescent signal was acquired using an Odyssey CLx (LI-COR) and quantification using ImageJ. The primary antibodies used were against the following: GAPDH (Cell Signaling, 2118S), HCMV ssDBP (Virusys, P1209), HCMV UL44 protein (Virusys, CA006-100), HCMV IE1 and IE2 (Abcam, ab53495), HCMV UL84 protein (Virusys, CA144-500), FLAG-M2 (Sigma-Aldrich, F3165), mCherry (Abcam, ab205402), MCMV IE1 and MCMV ssDBP (both were a kind gift from S. Jonjic). The secondary antibodies used were as follows: IRDye 680RD goat anti-rabbit (Li-COR LIC-92668071), IRDye 680RD goat anti-mouse (Li-COR, LIC-92668070) and goat anti-chicken IgY (H+L) conjugated to Alexa Fluor-647 (ThermoFisher Scientific, A-21449).

Genome editing detection assay {#sec024}
------------------------------

Total cell DNA was extracted and purified at 48 hpi using the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturers instructions. An \~800 bp gene RNA4.9 fragment, covering the target locations of all sgRNAs, was amplified using KAPA 2G Robust PCR kit (KAPABIOSYSTEMS; forward primer AGTGCGCATGCGTCGGTA, reverse primer ACCTACCGTCGTCGTCGG) and used with the Alt-R Genome Editing Detection Kit (IDT) according to the manufacturer's instructions.

Cloning of overexpression plasmids {#sec025}
----------------------------------

The UL57 gene was amplified from purified HCMV DNA using primers that contained an overlap with the lentiCRISPR v2 vector: forward primer ggaccggttctagagcgctgccaccATGAGCCACGAGGAACTAACCGCG, reverse primer gtttgttgcgccggatccTTACAACCGGCTGCGTTTGGCC; lower case characters represent the vector-overlapping regions). The vector was cut using XbaI and BamHI (NEB), and the UL57 fragment was cloned into it using the Gibson assembly method \[[@ppat.1008390.ref068]\].

The UL57 gene was amplified from the lentiCRISPR v2-derived plasmid (described above) using primers that contain XbaI or BamHI restriction sites and a flag sequence, adding it downstream to the UL57 sequence. The primers used were as follows: forward primer, gaccggttctagagATGAGCCACGAGGAACTAACC, reverse primer, aataggatccTTA*CTTGTCGTCATCGTCTTTGTAGTC*CAACCGGCTGCGTTTGG; lower case characters represent restriction sites, and italic characters represent the flag sequence). The vector and insert were cut using XbaI and BamHI (NEB) and the UL57-flag fragment was ligated into the vector overnight at 16°C.

The mCherry gene was inserted similarly into the lentiCRISPR v2 vector using restriction sites for AgeI and BamHI.

Lentiviral particles were generated by co-transfection of the lentiCRISPR v2-derived plasmids and second-generation packaging plasmids (psPAX2, Addgene\#12260; pMD2.G, Addgene\#12259) into HEK 293T cells using jetPEI DNA transfection reagent (Polyplus-transfection) according to the manufacturer's instructions. 48 hours post transfection, supernatants were collected and filtered through a 0.45 μm membrane (Millipore). Cells grown in 6-well plates were transduced with lentiviral vector particles in the presence of polybrene (8.33 μg/mL), selected at 48 hours post-transduction using 1.75 μg/mL puromycin, and infected at 3 days post-transduction. When RNA4.9 KD was performed, transduction with CRISPR plasmids was done prior to transduction of overexpression plasmids. Overexpression of mCherry was confirmed using fluorescent microscopy, and overexpression of ssDBP was confirmed by immunoblot in each experiment.

Supporting information {#sec026}
======================

###### RNA4.9 signal is RNA-specific.

**a)** Mock and HCMV Merlin strain-infected fibroblasts at 48 hpi (MOI = 5) were stained using fluorescent probes (white) against indicated HCMV lncRNAs. **b)** RNA4.9 was detected by RNA-FISH using fluorescent probes (white) in HCMV Merlin strain-infected fibroblasts at 48 hpi (MOI = 5). Cells were untreated, pretreated with DNase I or RNase A as indicated. **a-b)** Nuclei were counterstained with Hoechst (blue). **c)** At 48 hpi (MOI = 3), infected fibroblasts were fractionated into cytosolic (CYTO) and nuclear (NUC) fractions. Relative RNA4.9 and RNA2.7 levels were quantified using RT-qPCR and normalized to the cytosolic fraction and the cellular transcript ANXA5.

(TIF)

###### 

Click here for additional data file.

###### RNA4.9 KD using CRISPRi inhibits HCMV DNA replication and growth.

**a)** Fibroblasts transfected either with control siRNA or siRNAs targeting RNA1.2 and RNA4.9, respectively, were infected with HCMV Merlin strain (MOI = 1). Relative levels of RNA1.2 and RNA4.9 were quantified using RT-qPCR at 48 hpi, and normalized to the cellular transcript ANXA5. **b)** Fibroblasts transfected either with control ASOs or ASOs against RNA4.9, were infected with HCMV Merlin strain (MOI = 1). Relative levels of RNA1.2 and RNA4.9 were quantified using RT-qPCR at 48 hpi, and normalized to the cellular transcript ANXA5. **c-f)** Fibroblasts expressing dCAS9 and either a control sgRNA or one of two different sgRNAs targeting the RNA4.9 promoter (sgRNA3 and sgRNA9) were infected with HCMV Merlin strain (MOI = 0.1). **c)** Relative RNA4.9 levels were quantified using RT-qPCR at 48 hpi and normalized to the human transcript ANXA5. **d)** Relative viral DNA levels were quantified using qPCR at 48 hpi using UL55 primers, and normalized to the cellular gene B2M. **e)** Viral titers were measured 5 days post infection (dpi) by TCID50. **f)** Relative levels of the UL123 (IE1), UL44 and UL99 transcripts were quantified using RT-qPCR at 48 hpi and normalized to the cellular ANXA5 transcript. **c-f)** Values and error bars represent the average and SD of triplicates. A representative analysis of two independent experiments is shown. Two-sided *t*-test was applied (\*\*\*p-value\<0.001, \*\*p-value\<0.01, \*p-value\<0.05, NS, not significant).

(TIF)

###### 

Click here for additional data file.

###### RNA4.9-Cas9 KD does not directly affect viral gene expression.

Fibroblasts expressing CAS9 and either a control sgRNA or a sgRNA targeting the RNA4.9 promoter (sgRNA3) were infected with HCMV Merlin strain (MOI = 2) and treated with PFA. Relative levels of the indicated viral genes, including RNA4.9, were quantified using RT-qPCR at 48 hpi and normalized to the cellular transcript ANXA5.

(TIF)

###### 

Click here for additional data file.

###### RNA4.9-Cas9 KD does not affect UL84 expression and its recruitment to the viral replication compartment.

Fibroblasts expressing CAS9 and either a control sgRNA or a sgRNA targeting RNA4.9 (sgRNA3 or sgRNA5, as indicated) were infected with HCMV Merlin strain (MOI = 3). **a)** UL84 (red) was detected using IF at 48 hpi in the presence of PFA. **b)** Quantification of UL44 and UL84 protein levels from the immunoblot analysis in ([Fig 4D](#ppat.1008390.g004){ref-type="fig"}), normalized to the levels of GAPDH.

(TIF)

###### 

Click here for additional data file.

###### ssDBP is stabilized by viral DNA replication.

**a)** Relative expression of UL57 transcript during HCMV infection as measured by RNA-seq \[[@ppat.1008390.ref024]\]. **b)** Fibroblasts were infected with HCMV Merlin strain (MOI = 2) and harvested at the indicated time points post infection. Relative viral DNA levels were quantified using qPCR at the indicated time points, using UL44 primers and normalized to the cellular gene B2M.

(TIF)

###### 

Click here for additional data file.

###### Various sgRNAs lead to efficient Cas9 targeting.

Fibroblasts expressing CRISPR-Cas9 and five different sgRNAs targeting the RNA4.9 TSS region or a control sgRNA were infected with HCMV Merlin strain (MOI = 3), treated with PFA and harvested at 48 hpi. A T7 endonuclease I mismatch cleavage assay was conducted to estimate the genome editing efficiency of the RNA4.9 loci. The relative quantification of band intensities (which indicates a mutated sequence) is presented, normalized to the signal obtained using the control sgRNA.

(TIF)

###### 

Click here for additional data file.

###### ssDBP overexpression rescues the defect caused by interference with RNA4.9 expression.

**a-b)** Fibroblasts were infected with the Merlin Δ3' mutant or the parental strain (MOI = 1), treated with PFA, and harvested at 48 hpi. **a)** Relative RNA4.9 5' and 3' levels were quantified using RT-qPCR and normalized to the cellular ANXA5 transcript. **b)** ssDBP and IE1/2 were detected by immunoblot analysis. Human GAPDH was used as a loading control. **c-e)** Fibroblasts expressing mCherry as control (yellow) or ssDBP (orange) were infected, as indicated (MOI = 1), and harvested at 48 hpi. **c)** Relative RNA4.9 levels were quantified using RT-qPCR and normalized to the cellular ANXA5 transcript in fibroblasts expressing CRISPR-Cas9 and a sgRNA targeting the RNA4.9 TSS region (sgRNA3)or a control sgRNA and infected with the HCMV Merlin strain. **d)** Fibroblasts were infected with the OriShift mutant virus or the parental strain (AD169). Relative viral DNA levels were quantified by qPCR using UL44 primers, and normalized to the cellular gene B2M. **e)** Fibroblasts expressing CAS9 and either a control sgRNA or a sgRNA targeting RNA4.9 TSS region (sgRNA3) were infected with HCMV Merlin strain. Relative viral DNA levels were quantified using qPCR and UL44 primers, and normalized to the cellular gene B2M. **a, c-e)** Values and error bars represent the average and SD of triplicates. A representative analysis of two independent experiments is shown. Two-sided *t*-test was applied (\*\*\*p-value\<0.001, \*\*p-value\<0.01, n.d, not detected).

(TIF)

###### 

Click here for additional data file.

###### Kinetics of MCMV RNA1.6 expression.

**a)** Relative RNA1.6 transcript levels in MCMV Smith strain-infected MEFs (MOI = 1) were quantified by RT-qPCR at indicated time points post infection. RNA levels were normalized to the mouse GAPDH transcript. **b)** MEFs were either infected with MCMV Smith strain (MOI = 1) or left uninfected, and the infected cells were either treated or untreated with PFA. Relative RNA1.6 levels were quantified by RT-qPCR at 20 hpi. RNA levels were normalized to the mouse 18S rRNA. **a-b)** Values and error bars represent the average and SD of triplicates. A representative analysis of two independent experiments is shown.

(TIF)

###### 

Click here for additional data file.

###### Differential expression analysis of viral transcripts in RNA4.9 KD vs. control cells.

(XLSX)

###### 

Click here for additional data file.

###### smFISH probes sequences.

(XLSX)

###### 

Click here for additional data file.
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18 Nov 2019

Dear Dr. Stern-Ginossar,

Thank you very much for submitting your manuscript \"Human cytomegalovirus long noncoding RNA4.9 regulates viral DNA replication\" (PPATHOGENS-D-19-01898) for review by PLOS Pathogens. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. These issues must be addressed before we would be willing to consider a revised version of your study. We cannot, of course, promise publication at that time.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Additionally, to enhance the reproducibility of your results, PLOS recommends that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plospathogens/s/submission-guidelines#loc-materials-and-methods>

We hope to receive your revised manuscript within 60 days. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email. Revised manuscripts received beyond 60 days may require evaluation and peer review similar to that applied to newly submitted manuscripts.
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We are sorry that we cannot be more positive about your manuscript at this stage, but if you have any concerns or questions, please do not hesitate to contact us.
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\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Dear Naom,

I hope this finds you well. I have sent your manuscript to three experts in the Herpesvirus field who all have experience with Viral DNA replication. All three reviewers viewed your work as very important and appreciated the use of highly innovative tools to answer critical questions about HCMV replication. Their views were wide ranging on the acceptance of the manuscript and two reviewers (specifically \#2 and \#3) had significant issues with the interpretation and presentation of the data which undermined their support of the manuscript. I however find the manuscript of high value and am inclined to allow you to read the comments and see if you think they are addressable in a reasonable time frame. As such, I rendered a decision of Major Revision. If you are able to address the concerns of Reviewer \#s 2 & 3, I would be inclined to send it back to them for review. While this is not the decision you were hoping for, do understand that if you are able to accommodate those two reviewers, I will be highly supportive of the work.

Cheers,

Eain Murphy

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: Upon characterizing the subcellular distribution of the four major lncRNAs encoded by HCMV, Tai-Schmiedel et al commence this study by showing that RNA1.2, RNA2.7 and RNA5.0 accumulate in the cytoplasm of infected cells while RNA 4.9 largely accumulates within nuclear viral replication compartments. Using Crispr-cas9 and CRISPRi methods, the authors create the first hypomorphic functional allele for RNA4.9 that maintains the critical integrity of oriLyt, elegantly overcoming a significant impediment that has prevented the investigation of RNA4.9 function during HCMV reproduction. They conclusively show that interfering with RNA4.9 accumulation directly inhibits viral DNA synthesis and reduces virus productive growth. Furthermore, effects of RNA4.9 on virus gene expression were shown to be secondary to effects on DNA synthesis. Using DNA-RNA hybrid immunoprecipitation, the authors provide evidence that GC rich regions specifically from the RNA4.9 RNA are enriched in these structures. Finally, they present evidence that RNA4.9 post-transcriptionally controls levels of the HCMV UL57 ssDBP and that ectopic expression of ssDBP restores replication of recombinant viruses containing RNA4.9 hypomorphic alleles. A similar RNA4.9 counterpart is identified in MCMV and shown to regulate viral DNA replication.

The work is significant as it is the first to establish biological function for the HCMV lncRNA4.9 in viral DNA synthesis and characterize the phenotype of RNA4.9 hypomorphic alleles in the productive growth cycle. It uses creative cutting edge genome editing methods to overcome a key obstacle limiting genetic analysis in large viral genomes that encode overlapping cis and trans-acting functions within discrete, compact regions and creates the first hypomorphic allele of lncRNA4.9 that doesn\'t incidentally damage orilyt. Besides this creative engineering strategy, the experiments are well executed, the data are rigorous and compelling and the manuscript is well written. The work is of broad interest to many investigators studying the many roles of non coding RNAs in infection biology and seeking to engineer mutations in overlapping genes without damaging critical cis-acting regulatory elements. I have no substantial, essential comments that would significantly improve this already strong manuscript.

Reviewer \#2: The functions of the four long noncoding RNAs encoded by human cytomegalovirus are not well-characterized. This manuscript investigates the function of lncRNA4.9. The authors observe localization in the viral nuclear replication compartment during HCMV infection of fibroblasts. They apply a loss-of-function approach using gene editing in the lncRNA4.9 region. By this approach, they uncover an impact on viral DNA replication and the level of the viral ssDNA binding protein. A parallel approach in the MCMV system led to similar outcomes. The authors provide a model whereby the lncRNA4.9 binds the oriLyt to form an RNA-DNA hybrid that impacts the initiation of DNA replication and reduces ssDNA binding protein levels. However, the experimental approach used to edit the lncRNA4.9 will lead to dsDNA breaks that make the impact on oriLyt function and neighboring transcription very difficult to parse.

Reviewer \#3: The manuscript by Tai-Schmiedel at al. "Human cytomegalovirus long noncoding RNA4.9 regulated viral DNA replication" is an impressive paper. Many of their experiments answer some of the basic questions regarding the expression and localization of the viral lncRNAs. This is an important area of research given the abundance of the viral lncRNA and how little is known about the functions during viral replication. The identification of a RNA4.9 homologue in MCMV is an interesting discovery and extends the work to a possible mechanism used by other beta herpesviruses. There are concerns regarding the approach to KD RNA4.9 and the interpretation of the role of RNA4.9 in DNA replication given its overlap with oriLyt, and how UL57 (ssDBP) is regulated by RNA4.9. These concerns damp some of the enthusiasm for the manuscript. Specific questions are listed below.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: none.

Reviewer \#2: Major concern

1\. Their approach to knock-down the gene of interest using WT Cas9 will lead to complex and varied mutations and possibly indirect host DNA damage responses.

The authors have used gene-editing with wt Cas9 to generate dsDNA breaks in the CMV genomes. This is not an appropriate way to transiently knock-down a specific gene of interest in the context of infection (why not use siRNA?). This type of approach is especially troublesome in the area of the genome that houses both the origin of lytic replication and the regulatory region of the DNA replication proteins that is focused on. A break in this area can cause non-specific host DNA damage responses, loss-of-function of the origin and disruption of the normal architecture of the genome that mediates transcription of genes in that area. Given the complexity of this region and the lack of characterization of the ensuing genome edits, it is impossible to interpret the downstream effects. The use of multiple gRNAs and seeing disparate effects merely indicates the efficiency of edits and damaged genomes differs. Their control gRNA will likely not cut at all- they might want to target an innocuous region (this is obviously hard to do). They do not sequence the edited genomes. Cas9 systems lead to a spectrum of mutations. Conclusions about the direct effect of loss of the lncRNA4.9 can not be made using this approach.

If the authors wish to use this method to edit the virus, they might purify and characterize the mutants prior to use in infection experiments to better ensure that only lncRNA4.9 is directly impacted. This will be very difficult to do. More refined mutations such as disruption of initiation or insertion of a transcriptional stop would seem much cleaner.

The use of a mutant Cas9 that impairs transcription initiation is a more reasonable approach and there is one supplemental figure demonstrating an impairment in lncRNA expression and replication. How does the alteration of transcription in this region impact the 'firing' of the lytic origins? Rescue by ectopic lncRNA4.9 expression should be demonstrated.

2\. Experimental reproducibility and rigor throughout the paper.

In general, the MOI varies within each figure and across nearly all figures in the paper. This makes integration of RNA, DNA, Protein, and IFA data very difficult. Specific concerns with each figure are described below.

Figure 1.

1A appears to be previously published data. What was the cell type and MOI? How do these levels relate to coding transcripts typical of IE, E, L.

1B. What is the nuclear to cytoplasmic ratio? Why not show dual color as in 1C. Is there a software-based enumeration of this data so we can learn from hundreds of cells, not single cell staining?

1B-1C. Where is the mock control? MOI5.0 vs MOI1.0 in 1B. There is no direct demonstration of viral DNA replication compartments

Figure 2.

2A. There seem to be disparities in the impact on RNA, DNA, virus production between sgRNA3 and 5. The impact on gene expression seems to be greater with sgRNA3 at 24 hpi and with sgRNA5 at 48 hpi. Why was sgRNA 3 used moving forward?

Figure 3.

3A. This was based on one experiment. Why was a low MOI used for this? Why weren't more genes impacted.

3B. The normalization of this data is really difficult to understand. There is no data regarding the oriLyt.

Figure 4.

A and b. 24 hpi is shown without PFA and the 48 hr timepoint is with PFA. This is a strange comparison. PFA abolishes viral replication compartments, does this change the nuclear localization of RNA4.9?

C. Isn't it expected that PFA or anything that abrogates lytic replication will reduce viral gene expression?

D. no error bars

E. This should be provided with the exact coordinates of the sgRNAs used earlier in the manuscript.

Figure 5.

How many experimental replicates does this represent?

It is difficult to compare transcripts to protein. Such correlations are not very valuable and no viral DNA replication data is provided for reference. How is the quantitation of transcripts and proteins from an overexpressed gene informative? If PFA is used, what happens to ssDNADBP?

Figure 6.

Different sgRNAs in the lncRNA4.9 region have differential editing of the genome that leads to dsDNA breaks. This does not show a direct effect of one transcript to another.

Figure 7.

7D. This is an unusual mutant. Does the previous publication describe a replication defect at this MOI?

7F. Does ssDNA overexpression increase DNA copy number?

F and G. What was the statistical test used? The impact of ssDBP is very slight.

B-F, if you overexpress full-length lncRNA4.9, do you rescue ssDBP, replication and infectious virus production back to WT levels?

Figure 8.

A Where do the sgRNA bind and edit in MCMV? What are those edits?

3\. The model is not supported by the data.

There are no experiments using proteasome inhibitors to support premise of ssDNABP instability. No data for direct interaction of lncRNA4.9 with the oriLyt. No data for impact on nascent DNA replication or unwinding at oriLyt.

Reviewer \#3: The timing of the onset of DNA replication and the expression of RNA4.9 needs to be clarified. DNA replication begins around 24 hrs post infection. The expression kinetics of RNA4.9 needs to be confirmed at earlier time points before DNA replication begins in order to determine the role of RNA4.9 in DNA synthesis. The question is, what is the level of RNA4.9 between 24 and 36 hrs? The relationship between the levels of RNA4.9 and amount of newly synthesized DNA resulting in an increase in template which could be used to produce more RNA4.9. This brings into question if the results are really due to a decrease in RNA4.9 or if it is disrupting the cis-elements within oriLyt which would result in a decrease in DNA replication and then a decrease in RNA4.9. The other issue with the kinetics of RNA4.9 expression is that some of the experiments were performed at 24 hrs (Fig. 3 panel a) when they have not established that RNA4.9 is expressed at significant levels by 24 hpi. Fig. 1A extrapolates the levels of RNA4.9 from 24 to 72 hpi and it's not clear if RNA4.9 is an early transcript or expressed after the onset of DNA synthesis. The knockdown of RNA4.9 (Fig. 2 panel a) is at 48 hpi, but that is already after the onset of DNA replication at 24-36 hpi.

In regards to the CRISPR experiments (Fig. 2, Fig. 4 and Fig. 6), what was the percentage of HCMV genomes that carried the sgRNA induced RNA4.9 promoter mutation? The authors attempt to answer this question with the relative induced mutations shown in Figure S6 but it doesn't give an absolute value to how many genomes have the mutation since it is a relative comparison between the specific gRNA to the control gRNA.

This brings up another issue, the control elements within the origin and the RNA4.9 promoter. Promoters are often associated with activity of lytic origins, and the act of transcription is thought to help open the DNA for initiation of DNA synthesis or allow for assemble of the core enzymatic machinery. The SV40 promoter can functionally replace the HCMV oriLyt promoter, demonstrating that the act of transcription is an important process for oriLyt-dependent DNA replication. The RNA4.9 promoter may have additional functions beyond the expression of the RNA4.9 transcript, it may in fact be a control element within the origin for initiating. The authors have not ruled out the possibility that they are disrupting the function of the cis-elements in the origin. This is a very difficult issue to resolve but there is no evidence that the phenotype described is due to the disruption of the RNA4.9 promoter which causes a decrease in the expression of RNA4.9 or if the disruption of the RNA4.9 promoter is directly affecting the ability of the origin to function normally.

The R-loop within the origin has previously been described. In addition to the RNA4.9 R-loop there are other RNAs that have been identified from the origin. This was first reported in Prichard et al. J Virol. 1998 Sep;72(9):6997-7004 "Identification of persistent RNA-DNA hybrid structures within the origin of replication of human cytomegalovirus". Interestingly, the 5' region of RNA4.9 is within the transient plasmid-based replication assay and maybe functional in that system as well. The viral protein UL84 was also shown to interact with the stem-loop structure at the 5' region of the RNA-DNA hybrid in Colletti et al. J Virol. 2007 Jul;81(13):7077-85 "Human Cytomegalovirus UL84 Interacts with an RNA stem-loop sequence found within the RNA/DNA hybrid region of oriLyt".

Fig. 4 panel c and d. Based on the western blot it seems like there might also be a reduction in the amount of UL84 and UL44 protein in cells treated with the sgRNA3 and not a specific reduction in the ssDBP levels. The graph in panel d shows the ssDBP relative to GAPDH, what are the levels of UL84 and UL44 in the same graph. Additionally, with panel f what are the relative levels of early transcripts UL84 and UL44 compared to UL57?

Fig. 6 and 7. In figure 6 there is a decrease in RNA4.9 from the specific sgRNA and a decrease in UL57 RNA, while in Figure 7 there decrease in RNA4.9 in the OriShift mutant but the expression of UL57 is not significantly different in the WT and OriShift mutant (panel e). This difference in the amount of UL57 transcript detected (significantly different in cells where RNA4.9 is KD with Cas9 and sgRNA, but not significantly different in the oriShift mutant where RNA4.9 levels are reduced through genomic shifting) is not adequately discussion as to why there is an inconsistency in the method used to reduce RNA4.9 and the levels of UL57 that are reported.

Figure S2. The other compounding factor is if the CRISPRi protein, which binds to DNA to block transcription without the nuclease activity, could block the ability of the viral DNA initiation protein in a similar manner, and if that's true then the results could be due to the blocking IE2 or UL84 at the origin in addition to blocking transcription.

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: 1) It would be helpful to include a second guide RNA (ie:sgRNA5) in at least panel F of figure 4

2\) Does PFA treatment limit accumulation of ectopically expressed ssDBP flag in HCMV infected cells? This would be predicted to occur and is simple to test.

Editorial comments to address in the text:

Line 199-200 revise to state," We next tested the possibility that RNA4.9 KD affects ssDBP stability perhaps as an outcome of faulty unwinding of oriLyt. " 

Line 205, replace "started" with "first observed"

Line 207-209: As written, this is somewhat confusing, whereas it is very clear in the figure 9 legend. I think the authors are combining too much in a single sentence and as a result may make it harder for the generalist reader to separate experimental findings from more interpretative speculation.

Figure 5 and S5 legends: the authors measure DNA accumulation, which of course reflects DNA replication. The term "initiation", however, reflects a discrete phase of the replication process that is inferred by the authors, and while likely correct, has not been demonstrated experimentally. Perhaps the term "initiation" could be removed from the legend and retained in the text in the speculative manner in which it is already used by the authors.

Reviewer \#2: (No Response)

Reviewer \#3: Minor points:

Page 4 line 66-68: In regards to the reports of viral lncRNAs, Noriega et al. J Virol. 2014 Aug;88(16):9391-405 "Human cytomegalovirus modulates monocyte-mediated innate immune responses during short-term experimental latency in vitro" has also identified HCMV lncRNAs during latency.

\*\*\*\*\*\*\*\*\*\*
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If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Dear Dr. Stern-Ginossar,
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Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch within two working days with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.
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Dr Stern-Ginossar,

I have read your comments to reviewers and re-read your manuscript and it is in my opinion that you have improved the manuscript a great deal, took the suggestions seriously and have performed a significant amount of work to make this manuscript acceptable for publication without further review. It represents a nice body of work and you and your co-authors should be proud. Please contact me if there is any way I can be of assistance. Again, congratulations.

Cheers,

Eain A Murphy
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